NCTH

Prytime Medical Devices, Inc. Announces Appointment of Donna Syracuse as Chief Commercialization Officer

Retrieved on: 
Tuesday, November 21, 2023
SAN, Commercial, Cardiology, Intervention, Merit, Moyamoya disease, RN, Drainage, Patient, Dialysis, Region, Electrophysiology, NCTH, Nephrology, REBOA, Standard of care, Bleeding, Nursing care plan, Death, Growth, Hospital, Physician, Syracuse, Nursing, Angiography, Biopsy

SAN ANTONIO, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for noncompressible torso hemorrhage (NCTH), announced that Donna Syracuse, RN, has joined the company as Chief Commercialization Officer effective August 28, 2023.

Key Points: 
  • Donna Syracuse has over 25 years of Commercial and Nursing Leadership in critical care, nephrology, cardiology, peripheral vascular disease, and electrophysiology.
  • Focused on clinical outcomes and evidence development, Donna was key in developing the HeRO® Graft market from launch to becoming Standard of Care for dialysis patients.
  • "I'm excited to join Prytime Medical at this point of its growth," said Donna.
  • "Donna's experience fits perfectly with Prytime's strategic goal for building outcomes-driven REBOA programs," said David Spencer, Prytime Medical CEO.

Prytime Medical Announces Appointment of New Chief Medical Officer

Retrieved on: 
Tuesday, November 8, 2022
Trauma, Medicine, Cardiothoracic surgery, Iran National Science Foundation, Molecular biology, W. L. Gore & Associates, Physician, Vascular surgery, Industry, University, Adoption, FDA, Patient, National Science Foundation, American Heart Association, National Institutes of Health Clinical Center, REBOA, Technology, Department, SAN, National Institute, PLUS, Associate, Resuscitation, NSF, CMO, Pathology, Bleeding, AHA, NIH, Duke University Hospital, Leadership, Health, NCTH, Clinical trial, Research, Program, Intellectual property, United States Department of Defense, Medical device

SAN ANTONIO, Nov. 8, 2022 /PRNewswire-PRWeb/ -- Prytime Medical Inc - The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for noncompressible truncal hemorrhage (NCTH), today announced the hiring of Chief Medical Officer, Jeffrey H. Lawson, M.D., Ph.D.

Key Points: 
  • SAN ANTONIO, Nov. 8, 2022 /PRNewswire-PRWeb/ -- Prytime Medical Inc - The REBOA Company, the leading innovator and global provider of lifesaving REBOA products for noncompressible truncal hemorrhage (NCTH), today announced the hiring of Chief Medical Officer, Jeffrey H. Lawson, M.D., Ph.D.
    "The new technology that Prytime Medical has recently developed was designed specifically to aid in resuscitation and the management of non-compressible hemorrhage" said Dr. Jeff Lawson.
  • "Prytime Medical has fundamentally changed its overall strategy," said David Spencer CEO.
  • As a medical technology veteran, Dr. Lawson has served as CMO, President and Chief Executive Officer at Humacyte, Inc.
  • Prytime Medical Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control.

Centerline Biomedical Launches Research and Development Collaboration with Air Force

Retrieved on: 
Thursday, May 12, 2022
Air force, AR, Department, Death, United States Air Force School of Aerospace Medicine, R, Atmosphere of Earth, Summit Medical Group, Medicine, Multimedia, Patient, Brooke Army Medical Center, Trauma, Health, Center line, IOPS, NCTH, Joint Base San Antonio, Defense, Nanoparticle, Research, FDA, MDW, Bleeding, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, Calendar, The, Biomedicine, Blood, Medical device

CLEVELAND, May 12, 2022 /PRNewswire/ -- Centerline Biomedical, Inc. (Centerline) announced Thursday that the Cleveland-based startup company has launched work on a contract to apply its IOPS™ technology platform to service the needs of its collaborators at the 59th Medical Wing (59 MDW), the Air Force's premier healthcare, medical education and research, and readiness wing, located at Joint Base San Antonio-Lackland.

Key Points: 
  • Centerline Research and Development (R&D) personnel are collaborating with researchers led by Lt. Col. Thomas Percival, Cardiothoracic Surgeon at the Air Force 59 MDW, 959th Medical Group at the Brooke Army Medical Center.
  • NCTH is the leading cause of potentially preventable military trauma deaths, as well as a leading cause of death in civilian trauma cases such as motor vehicle collisions.
  • This advanced R&D collaboration is being undertaken in the context of the company's commercial launch of its first FDA-cleared IOPS product.
  • "Our team is delighted to be collaborating with Dr. Percival and his colleagues at the Air Force," shared company CTO Vikash Goel, who has been selected three times to present at the Military Health System Research Symposium.